Global Renal Denervation Devices Market (2020 to 2025) – Growth, Trends, and Forecasts –

The "Renal Denervation Devices Market – Growth, Trends, and Forecast (2020 – 2025)" report has been added to’s offering.
The major factors responsible for the growth of the renal denervation devices market include the rising prevalence of hypertension and the long-lasting effect of the procedure.
High blood pressure is called hypertension. The prevalence of hypertension has been observing a significant rise, over the past few years. Generally, blood pressure rises and falls throughout the day, but it can damage one’s heart and result in health problems if hypertension stays high for a long time.
According to the CDC (Centers for Disease Control and Prevention), about 75 million American adults (32%) have high blood pressure (hypertension), but only about half (54%) of them, with high blood pressure, have their condition under control. High blood pressure had been the primary contributing cause of death for more than 410,000 Americans, in 2014. CDC also stated that high blood pressure costs the country USD 48.6 billion, every year. The high prevalence is not just limited to the United States, owing to the fact that the European and South Asian countries also have a high rate of hypertension, which makes this a global problem.
On the other hand, only a few renal denervation devices have only been approved in Europe, while the major players have been gaining approval for the clinical trials from the FDA, in the United States. Thus, owing to all of the aforementioned factors, the market studied is expected to witness high growth, in the coming years.
Companies Mentioned

  • Medtronic PLC
  • St. Jude Medical Inc.
  • ReCor Medical Inc.
  • Ablative Solutions Inc.
  • Mercator MedSystems
  • Terumo Corporation
  • Symple Surgical
  • Abbott Laboratories

Key Market Trends
The Ultrasound-based Segment is Expected to be the Fastest Growing Segment
The ultrasound-based renal denervation devices are a minimally invasive procedure, using ultrasound to ablate nerves in the wall of the renal arteries, and it disrupts the transmission of nerve impulses to and from the kidney and lowers blood pressure. Additionally, according to the first randomized trial to compare the techniques (RADIOSOUND-HTN trial), the ultrasound-based renal denervation (RDN) approach has led to greater reductions in blood pressure than radiofrequency ablation in patients, with resistant hypertension. The rising prevalence of hypertension is expected to boost the overall growth of the market studied.
Europe is Expected to Dominate the Market
Europe has been found to hold a major share for the renal denervation devices market, and it is expected to show a similar trend over the forecast period, without significant fluctuations. According to the data published by Public Health England, high blood pressure affects more than one in four adults in England. There is a large number of renal denervation devices, which have received CE approval, in Europe. The major factor driving the growth of the market studied is rising R&D activities for the development of efficient devices. As per the, one of the market players, Abbott Medical Devices, completed the observational study of the EnligHTN renal denervation system, in Europe, in February 2019. Additionally, rising cases of drug-resistant hypertension may boost the overall growth of the market, over the forecast period.
Key Topics Covered:
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Hypertension
4.2.2 Long Lasting Effect of the Procedure
4.3 Market Restraints
4.3.1 Painful Procedure
4.3.2 Stringent Approval Process for Renal Denervation Devices and Reimbursement Systems
4.4 Porter’s Five Forces Analysis
5.1 By Technology
5.1.1 Radiofrequency-based
5.1.2 Ultrasound-based
5.1.3 Micro-infusion-based
5.2 Geography
5.2.1 North America
5.2.2 Europe
5.2.3 Asia-Pacific
5.2.4 Middle East & Africa
5.2.5 South America
6.1 Company Profiles
6.1.1 Medtronic PLC
6.1.2 St. Jude Medical Inc.
6.1.3 ReCor Medical Inc.
6.1.4 Ablative Solutions Inc.
6.1.5 Mercator MedSystems
6.1.6 Terumo Corporation
6.1.7 Symple Surgical
6.1.8 Abbott Laboratories
For more information about this report visit
View source version on
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 01/27/2021 11:17 AM/DISC: 01/27/2021 11:17 AM